Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001055466 | SCV001219859 | uncertain significance | Acute myeloid leukemia | 2023-08-25 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with CEBPA-related conditions. This variant is present in population databases (rs770636941, gnomAD 0.5%), including at least one homozygous and/or hemizygous individual. This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 22 of the CEBPA protein (p.Pro22Ser). ClinVar contains an entry for this variant (Variation ID: 851134). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CEBPA protein function. |
| Ambry Genetics | RCV004977943 | SCV005558711 | likely benign | Inborn genetic diseases | 2024-08-21 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |